S
Synlogic, Inc. (SYBX)
PNK – Real Time Price. Currency in USD
0.68
+0.00 (0.44%)
At close: Jun 26, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
PNK – Real Time Price. Currency in USD
0.68
+0.00 (0.44%)
At close: Jun 26, 2026, 4:00 PM EDT
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
| Name | Position |
|---|---|
| Dr. James J. Collins Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Advisor |
| Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Ms. Mary Beth Dooley | Principal Executive Officer & Principal Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-14 | 10-Q | sybx-20260331.htm |
| 2026-04-30 | 10-K/A | sybx-20251231.htm |
| 2026-03-12 | 10-K | sybx-20251231.htm |
| 2026-01-29 | 8-K/A | sybx-20260116.htm |
| 2026-01-20 | 8-K | sybx-20260116.htm |
| 2025-12-16 | 8-K | sybx-20251215.htm |
| 2025-11-26 | 8-K | sybx-20251121.htm |
| 2025-11-13 | 10-Q | sybx-20250930.htm |
| 2025-11-12 | DEF 14A | sybx-20251112.htm |
| 2025-11-12 | ARS | sybx_12.31.2024_ars.pdf |